Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 129

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 129
---
 operational and organic net sales growth and adjusted net income attributable to Boston Scientific common stockholders, exclude certain items required by generally accepted accounting principles in the United States (GAAP), are not prepared in accordance with GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures. 

33

The following is a reconciliation of our results of operations prepared in accordance with GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:

 Three Months Ended March 31, 2025(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$805 $133 $672 $(2)$674 $0.45 Non-GAAP adjustments:Amortization expense219 30 189 2 187 0.13 Acquisition/divestiture-related net charges (credits)149 (4)154—1540.10 Restructuring and restructuring-related net charges (credits)49 742—420.03 Investment portfolio net losses (gains) and impairments8 27—70.00 European Union (EU) Medical device regulation (MDR) implementation costs12 211—110.01 Deferred tax expenses (benefits)— (47)47—470.03 Adjusted$1,243 $122 $1,121 $0 $1,121 $0.75 

 Three Months Ended March 31, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$608 $115 $493 $(1)$495 $0.33 Non-GAAP adjustments:Amortization expense214 29 184 2 182 0.12 Acquisition/divestiture-related net charges (credits)64 (13)77 — 77 0.05